Novartis AG (SWX:NOVN)
122.08
+0.54 (0.44%)
Jun 12, 2026, 5:31 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.52B USD in the quarter ending March 31, 2026, a decrease of -0.70%. This brings the company's revenue in the last twelve months to $56.58B, up 6.31% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth.
Revenue (ttm)
$56.58B
Revenue Growth
+6.31%
P/S Ratio
4.92
Revenue / Employee
$751.70K
Employees
75,267
Market Cap
223.47B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Sandoz Group AG | 8.85B |
| Alcon | 8.53B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 4.16B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.61B |
Novartis AG News
- 2 days ago - Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) - GlobeNewsWire
- 2 days ago - Novartis says rare muscle disease drug shows promise in early trial - Reuters
- 3 days ago - Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
- 3 days ago - Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint - GlobeNewsWire
- 4 days ago - Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines - Business Wire
- 6 days ago - Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 - GlobeNewsWire
- 10 days ago - Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years - GlobeNewsWire
- 11 days ago - Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients - GlobeNewsWire